DXCM logo DexCom +
DexCom
+

DexCom (DXCM) Business News

Track DexCom in real time with a live news feed covering DexCom stock news, official press releases, company announcements, and an archive of historical DexCom news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
7:00 AM | Thursday | Jul 23, 2026 Business Wire

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

News Thumbnail
5:15 PM | Wednesday | Jul 22, 2026 Business Wire

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

News Thumbnail
4:45 PM | Monday | Jul 13, 2026 Business Wire

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

News Thumbnail
8:30 AM | Thursday | Jul 9, 2026 Business Wire

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

News Thumbnail
12:27 PM | Friday | Jul 3, 2026 PRNewsWire

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

News Thumbnail
9:00 AM | Tuesday | Jun 23, 2026 Business Wire

Dexcom Further Advances Vision of Glucose Biosensing for All

News Thumbnail
2:45 PM | Saturday | Jun 6, 2026 Business Wire

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

News Thumbnail
9:00 AM | Thursday | Jun 4, 2026 Business Wire

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026 Business Wire

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

News Thumbnail
9:30 AM | Tuesday | May 26, 2026 Business Wire

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

News Thumbnail

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

Business Wire

7:00 AM | Thursday | Jul 23, 2026

news photo
Loading...

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.

Read full article redirect
7:00 AM | Thursday | Jul 23, 2026

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

Business Wire

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th.

Read full article arrow
News Thumbnail
5:15 PM | Wednesday | Jul 22, 2026

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Participation in the TEMPO pilot will allow Dexcom.

Read full article arrow
News Thumbnail
4:45 PM | Monday | Jul 13, 2026

Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes

Business Wire

BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. Dexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real‑time glucose readings for an industry‑leading 15.5 days5. Building on the performance of Dexcom CGM whi.

Read full article arrow
News Thumbnail
8:30 AM | Thursday | Jul 9, 2026

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day.
The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will.

Read full article arrow
News Thumbnail
12:27 PM | Friday | Jul 3, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Read full article arrow
News Thumbnail
9:00 AM | Tuesday | Jun 23, 2026

Dexcom Further Advances Vision of Glucose Biosensing for All

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of milestones that advance its vision of making glucose biosensing more accessible. Notably, the company announced pediatric clearance for the Stelo Glucose Biosensor and the launch of its fully reimagined Stelo app experience in July for Apple iPhone and Android users in the United States.“Glucose matters for everyone and better understanding it can h.

Read full article arrow
News Thumbnail
2:45 PM | Saturday | Jun 6, 2026

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of.

Read full article arrow
News Thumbnail
9:00 AM | Thursday | Jun 4, 2026

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association's Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e.

Read full article arrow
News Thumbnail
9:30 AM | Tuesday | Jun 2, 2026

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

Business Wire

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights.

Read full article arrow
News Thumbnail
9:30 AM | Tuesday | May 26, 2026

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

Business Wire

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified.

Read full article arrow
News Thumbnail